MedPath

Boryung Pharmaceutical's BR-6002 Advances in Cardiovascular Disease Treatment

  • Boryung Pharmaceutical is developing BR-6002, an orally administered drug, for cardiovascular diseases, as well as gastric and duodenal ulcers.
  • BR-6002's development leverages GlobalData's predictive analytics for assessing the likelihood of approval based on historical drug development data.
  • Boryung Pharmaceutical focuses on chronic diseases, including hypertension, dyslipidemia, diabetes, CNS disorders, and cancers, with BR-6002 potentially expanding their cardiovascular portfolio.
Boryung Pharmaceutical is advancing the development of BR-6002, an orally administered drug, targeting cardiovascular diseases, gastric ulcers, and duodenal ulcers. The drug's progress is being monitored using GlobalData's predictive analytics to assess its likelihood of approval.
Boryung Pharmaceutical, headquartered in Seoul, South Korea, focuses on manufacturing and distributing pharmaceutical products for chronic diseases. Their portfolio includes treatments for hypertension, dyslipidemia, diabetes, CNS disorders, and cancers. BR-6002 could potentially expand their offerings in the cardiovascular space.
GlobalData's Likelihood of Approval (LoA) analytics tool assesses the probability of a drug's success in clinical development and eventual approval. This tool uses machine learning and a proprietary algorithm to process data from GlobalData’s Pharmaceutical Intelligence Center, providing insights into drug-specific phase transition and LoA scores.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Bitterroot Bio's BRB-002 Shows Promise in Phase 1 Trial for Atherosclerosis

Bitterroot Bio announced positive Phase 1 results for BRB-002, an immune-modulating protein therapy targeting CD47, in healthy volunteers.

Baili Tianheng's Novel Bispecific ADC Receives Fifth Breakthrough Therapy Designation for Small Cell Lung Cancer

BL-B01D1, a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC), has received breakthrough therapy designation from China's NMPA for recurrent small cell lung cancer. This marks the drug's fifth breakthrough designation, highlighting its potential across multiple cancer indications including lung, breast, and nasopharyngeal cancers.

Advancements in Antibiotic Development for Gram-Negative Bacteria

Spero Therapeutics is making significant strides in the development of antibiotics targeting Gram-negative bacteria, with a focus on treatments for complicated urinary tract infections, acute pyelonephritis, and multidrug-resistant infections. Their pipeline includes Tebipenem HBr, an oral carbapenem, and SPR206, an intravenous polymyxin analogue, both undergoing clinical trials.

BiPER Therapeutics Secures €800,000 to Advance BiP Inhibitor for Gastrointestinal Cancers

BiPER Therapeutics has secured €800,000 in bridge funding to advance its lead candidate, BPR001-615, a first-in-class BiP inhibitor, towards clinical trials.

FDA Grants Accelerated Approval to Zanidatamab for HER2+ Biliary Tract Cancer

The FDA has granted accelerated approval to zanidatamab-hrii (Ziihera) for treating adults with previously treated unresectable or metastatic HER2+ biliary tract cancer (BTC).

Cothera Bioscience's PC-002 Receives FDA Fast Track for Burkitt Lymphoma

Cothera Bioscience's PC-002, a first-in-class DUB inhibitor, has been granted Fast Track designation by the FDA.

Volixibat Receives FDA Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

The FDA granted Breakthrough Therapy Designation to volixibat for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC).

Basking Biosciences Initiates Phase II Trial of BB-031 for Acute Ischemic Stroke

Basking Biosciences has dosed the first subject in its Phase II RAISE trial evaluating BB-031 for acute ischemic stroke (AIS).

Bispecific Antibody-Drug Conjugates Show Promise in Solid Tumor Treatment

Bispecific antibody-drug conjugates (BsADCs) are emerging as a cutting-edge approach in cancer therapy, combining bispecific antibody precision with antibody-drug conjugate potency.

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial

InflaRx N.V. announced that its drug GOHIBIC (vilobelimab) has been chosen by BARDA for a Phase 2 clinical trial to explore new treatments for acute respiratory distress syndrome (ARDS), a life-threatening lung condition with no currently approved therapy.

Reference News

[1]
BR-6002 by Boryung Pharmaceutical for Cardiovascular Disease: Likelihood of Approval
pharmaceutical-technology.com · Sep 8, 2024

BR-6002, developed by Boryung Pharmaceutical, targets cardiovascular disease, gastric ulcers, and duodenal ulcers via or...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy